Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia
WolverHeme Happy Hour
00:00
The Role of Antibodies in CD20 Activation
Rituxim was the first as you all know and that's a type 1 antibody. Another type 1 monoclonal antibody was OFA Tumumab. That one works very similar to Rituximab. Obinituzumab is a type 2 antibody. It apparently binds closer to the cell membrane of the B cell via I think like a small loop or something of the CD20 receptor. And so in theory it should have more complement dependent cellular cytotoxicity. Not cellular. Compliment dependent cytot toxicity.
Play episode from 05:34
Transcript
